RANI (Rani Therapeutics Holdings) Total Assets: $51.88 Mil (As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.76
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Total Assets?

Rani Therapeutics Holdings RANI +3.91% 32 Total Assets is $51.88 Mil as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Rani Therapeutics Holdings's Total Assets for the quarter that ended in Mar. 2026 was $51.88 Mil.

During the past 12 months, Rani Therapeutics Holdings's average Total Assets Growth Rate was 2.50% per year. During the past 3 years, the average Total Assets Growth Rate was -2.30% per year. During the past 5 years, the average Total Assets Growth Rate was 7.50% per year.

During the past 7 years, Rani Therapeutics Holdings's highest 3-Year average Total Assets Growth Rate was 13.80%. The lowest was -2.30%. And the median was 11.85%.

Total Assets is connected with ROA %. Rani Therapeutics Holdings's annualized ROA % for the quarter that ended in Mar. 2026 was -50.92%. Total Assets is also linked to Revenue through Asset Turnover. Rani Therapeutics Holdings's Asset Turnover for the quarter that ended in Mar. 2026 was 0.03.

Rani Therapeutics Holdings  (NAS:RANI) Total Assets Explanation

Total Assets is connected with ROA %.

Rani Therapeutics Holdings's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-28.132/( (58.621+51.879)/ 2 )
=-28.132/55.25
=-50.92 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Rani Therapeutics Holdings's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=1.708/( (58.621+51.879)/ 2 )
=1.708/55.25
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Rani Therapeutics Holdings Total Assets Related Terms

Rani Therapeutics Holdings Total Assets Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings Total Assets Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 124.21 108.03 57.92 36.63 58.62

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.13 16.90 10.14 58.62 51.88
RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Rani Therapeutics Holdings's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=41.512+17.109
=58.62

Rani Therapeutics Holdings's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=35.543+16.336
=51.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $51.88 Mil mean?
Rani Therapeutics Holdings (RANI) has a Total Assets of $51.88 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' Total Assets too high?
Rani Therapeutics Holdings' current Total Assets is $51.88 Mil. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Total Assets compare to IBIO and RNTX?
Rani Therapeutics Holdings' Total Assets of $51.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current Total Assets is $51.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Total Assets of $51.88 Mil. The current Total Assets is $51.88 Mil. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Total Assets is $51.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price